ARTICLE | Company News
Cytogen deal
October 10, 1994 7:00 AM UTC
The Princeton, N.J., company signed a letter of intent to grant The DuPont Merck Pharmaceutical Co.'s radiopharmaceuticals division exclusive U.S. marketing rights to Samarium153 EDTMP. Samarium is in a Phase III trial to treat bone pain caused when cancer spreads to the bone. ...